On August 30, 2023 Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, reported that Joseph Tucker, Ph.D., Chief Executive Officer, will deliver a virtual presentation at the H.C. Wainwright 25th Wainwright Global Conference taking place from September 11 – 13, 2023 (Press release, Enveric Biosciences, AUG 30, 2023, View Source [SID1234634772]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Enveric’s participation are as follows:

Event:

H.C. Wainwright 25th Annual Global Conference

Date & Time:

Presentation available starting at 7:00 a.m. ET on September 11

Location:

Virtual

During the conference, members of Enveric’s management team will be available for virtual one-on-one-meetings with registered investors. An archived webcast of the presentation will be available starting on September 12, 2023 on the events and presentations section of the Company’s website.